Allogene Therapeutics ALLO Operating Lease ROU Assets
Operating Lease ROU Assets at other companies
Other financials
Where this comes from
Reported directly by Allogene Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent.
The source filing: Allogene Therapeutics’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 4:05 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-034585
Operating lease liabilities are based on the net present value of the remaining lease payments over the remaining lease term. In determining the present value of lease payments, the Company uses its estimated incremental borrowing rate. The weighted average discount rate used to determine the operating lease liability was 6.50%. As of March 31, 2026, the weighted average remaining lease term for the Company’s operating leases is 6.94 years.
Item 1. Financial Statements - Unaudited
FAQ
- What is Allogene Therapeutics's operating lease ROU assets?
- Allogene Therapeutics (ALLO) reported operating lease ROU assets of 6.5% in Q1 2026.
- How has Allogene Therapeutics's operating lease ROU assets changed year-over-year?
- Allogene Therapeutics's operating lease ROU assets increased by 3.8% year-over-year, from 6.3% to 6.5%.
- What is the long-term trend for Allogene Therapeutics's operating lease ROU assets?
- Over 5 years (2020 to 2025), Allogene Therapeutics's operating lease ROU assets has grown at a -0.7% compound annual growth rate (CAGR), from 4,129,500,000% to 3,988,800,000%.
- What does operating lease ROU assets mean?
- Right-of-use assets representing the lessee's right to use leased property over the lease term under ASC 842 operating lease classification.
Ask your AI about Allogene Therapeutics's operating lease rou assets.
Connect your AI assistant and compare it to peers, right in your chat.
